A Phase 1-2 and Pharmacologic Study of MM-111 in Patients with Advanced Refractory Her2 Positive Cancers
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The main purpose of this study is to learn the dose of MM-111 that does not cause unacceptable side effects.
Description
The main purpose of this study is to learn the dose of MM-111 that does not cause unacceptable side effects.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1011003553
